3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
6
Unknown
4
Terminated
2
Recruiting
2
No longer available
1
Active not recruiting
1
Sponsor Class
OTHER
24
OTHER_GOV
3
INDUSTRY
2
FED
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
429
Breast Neoplasms
298
Neoplasms
296
Colorectal Neoplasms
242
Neoplasm Metastasis
197
Ovarian Neoplasms
171
Lung Neoplasms
150
Recurrence
147
Prostatic Neoplasms
146
Pancreatic Neoplasms
142
Multiple Myeloma
136
Stomach Neoplasms
129
Squamous Cell Carcinoma of Head and Neck
128
Melanoma
123
Leukemia, Myeloid, Acute
115
Endometrial Neoplasms
115
Advanced Solid Tumors
113
Advanced Solid Tumor
108
Carcinoma, Hepatocellular
102
Triple Negative Breast Neoplasms
101
Small Cell Lung Carcinoma
88
Uterine Cervical Neoplasms
86
Lymphoma, Non-Hodgkin
83
Carcinoma, Renal Cell
72
Lymphoma, Follicular
71
Lymphoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
65
Solid Tumor
64
Lymphoma, Large B-Cell, Diffuse
64
Hematologic Neoplasms
62
Interventions
atezolizumab
1
Bevacizumab
1
2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
INDUSTRY
×
Fibrosis
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled
NCT05201404
2025-04-29
LIVERATION
Can-Fite BioPharma
Phase 3
Recruiting
471 enrolled